BUY TAMOXIFEN CITRATE (NOLVADEX) (20 MG/TAB. – 50 TABS)
Main Description
Tamoxifen Citrate 20 is an oral tablet containing 20 mg of tamoxifen citrate, a non-steroidal selective oestrogen receptor modulator (SERM). According to the supplied product information, tamoxifen works primarily by competing with oestrogen for binding sites in target tissues, particularly breast tissue. This mechanism distinguishes tamoxifen from aromatase inhibitors, which reduce the production of oestrogen by inhibiting the aromatase enzyme.
The supplied information describes tamoxifen citrate as an anti-oestrogen and oestrogen antagonist. Its principal pharmacological activity is associated with interaction with oestrogen receptors. Tamoxifen has been extensively studied in the context of hormone-responsive breast cancer and is used clinically in specific oncology settings.
Each tablet contains 20 mg of tamoxifen citrate and is intended for oral administration. The product is supplied as 50 uncoated tablets in one bottle and is identified in the supplied information as a prescription medicine manufactured by Hilma Biocare.
Key Product Information
Product: Tamoxifen Citrate (Nolvadex)
Strength: 20 mg per tablet
Active ingredient: Tamoxifen citrate
Dosage form: Uncoated tablet
Route: Oral
Pack size: 50 tablets
Molecular formula: C26H29NO
Molecular weight: 371.51456 g/mol
CAS number: 54965-24-1
Market status: Prescription
Company: Hilma Biocare
Clinical Pharmacology
Tamoxifen citrate exerts its pharmacological effects through interaction with oestrogen receptors. The supplied information states that tamoxifen competes with oestradiol for oestrogen-receptor protein in human breast adenocarcinoma tissue.
Following oral administration, the supplied information reports that an average peak plasma concentration following a single 20 mg dose occurs at approximately five hours. Tamoxifen undergoes extensive metabolism, with N-desmethyl tamoxifen identified as its major metabolite. The terminal elimination half-life of tamoxifen is reported as approximately 5–7 days, while the supplied information gives a longer approximate half-life for its major metabolite.
Indications and Uses
The supplied product information lists tamoxifen citrate for several clinical applications, particularly in oncology. These include:
Adjuvant treatment of breast cancer.
Treatment of certain axillary node-negative breast cancers.
Treatment of ductal carcinoma in situ.
Reduction of breast cancer risk in certain high-risk women.
Treatment of metastatic mammary carcinoma in specified patients.
The supplied information also describes uses in certain fertility-related conditions and male patients with elevated oestrogen levels. These uses require appropriate medical assessment and should not be interpreted as a recommendation for self-treatment.
Contraindications
According to the supplied product information, tamoxifen is contraindicated in patients with known hypersensitivity to tamoxifen or its ingredients. The source also lists a history of deep-vein thrombosis, stroke, uterine malignancies, pulmonary embolism, certain ocular disorders and hypercalcaemia among contraindications or significant precautions.
The supplied information specifically states that tamoxifen should be used only under the care of a physician.
Warnings and Precautions
Tamoxifen may increase fertility in some women and may cause fetal harm. The supplied information also identifies serious hepatic and thromboembolic events as potential concerns.
Appropriate clinical monitoring may include complete blood count (CBC) and liver function testing, depending on the patient’s circumstances and the prescribing clinician’s judgement.
Patients should inform their doctor about existing medical conditions and all medicines they take before starting treatment.
Adverse Reactions
The supplied product information reports possible adverse reactions including nausea, vomiting, hot flushes, dizziness, headache, depression, changes in vision, cataracts, retinopathy, thromboembolic events, peripheral oedema and changes in liver enzymes.
Other reported effects include altered menstruation, vaginal bleeding, ovarian cysts or pelvic pain, hair thinning or hair loss, vaginal dryness and changes in serum triglycerides.
Some symptoms, including difficulty breathing, facial or throat swelling, sudden weakness or numbness, chest pain or significant visual changes, require prompt medical attention.
Drug Interactions
Tamoxifen may interact with other medicines. The supplied information specifically discusses interactions with coumarin-type anticoagulants and recommends careful monitoring of prothrombin time when these medicines are used together.
The source also states that concomitant administration with certain medicines, including letrozole, anastrozole, phenobarbital, aminoglutethimide or corticosteroids, may affect tamoxifen serum levels. Bromocriptine may increase tamoxifen concentrations.
A doctor or pharmacist should review all prescription medicines, non-prescription medicines and supplements before treatment.
Dosage and Administration
The supplied source contains different dosage schedules depending on the clinical indication, including regimens for oncology and certain male indications. Because tamoxifen is a prescription medicine and dosing depends on the diagnosis, patient characteristics and treatment objective, the prescribing physician should determine the appropriate dose and treatment duration.
The dosage information supplied for specific male uses should not be used as an individual treatment protocol or as guidance for self-medication.
Presentation
Tamoxifen citrate 20 mg uncoated tablets, supplied as 50 tablets in one bottle.
Storage
Store in a cool, dry place between 15–25°C and protect from light.
